BR112017004812A2 - tratamento de fibrodisplasia ossificante progressiva - Google Patents

tratamento de fibrodisplasia ossificante progressiva

Info

Publication number
BR112017004812A2
BR112017004812A2 BR112017004812A BR112017004812A BR112017004812A2 BR 112017004812 A2 BR112017004812 A2 BR 112017004812A2 BR 112017004812 A BR112017004812 A BR 112017004812A BR 112017004812 A BR112017004812 A BR 112017004812A BR 112017004812 A2 BR112017004812 A2 BR 112017004812A2
Authority
BR
Brazil
Prior art keywords
acvr2a
acvr2b
acvr1
type
receptor antagonist
Prior art date
Application number
BR112017004812A
Other languages
English (en)
Other versions
BR112017004812B1 (pt
Inventor
N Economides Aris
J Hatsell Sarah
J Idone Vincent
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112017004812A2 publication Critical patent/BR112017004812A2/pt
Publication of BR112017004812B1 publication Critical patent/BR112017004812B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

a presente invenção refere-se a métodos para o tratamento de fibrodisplasia ossificante progressiva (fop). estes métodos envolvem administrar a um indivíduo que tem fop um regime eficaz de um antagonista do receptor de ativina tipo 2a (acvr2a) e/ou do receptor de ativina tipo 2b (acvr2b) ou um antagonista do receptor de ativina tipo 1 (acvr1). os antagonistas incluem proteínas de fusão de um ou mais domínios extracelulares (ecds) de acvr2a, acvr2b e/ou acvr1 e do domínio fc de uma cadeia pesada de imunoglobulina e anticorpos contra acvr2a, acvr2b, acvr1 ou ativina a.
BR112017004812-4A 2014-09-12 2015-09-14 Uso de um anticorpo contra ativina a para preparação de um medicamento para tratamento de fibrodisplasia ossificante progressiva BR112017004812B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462049869P 2014-09-12 2014-09-12
US62/049,869 2014-09-12
US201562141775P 2015-04-01 2015-04-01
US62/141,775 2015-04-01
PCT/US2015/000100 WO2016039796A2 (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Publications (2)

Publication Number Publication Date
BR112017004812A2 true BR112017004812A2 (pt) 2017-12-12
BR112017004812B1 BR112017004812B1 (pt) 2023-09-05

Family

ID=

Also Published As

Publication number Publication date
CN107106648B (zh) 2021-06-11
ZA201702112B (en) 2018-05-30
SG11201701913SA (en) 2017-04-27
IL251063A0 (en) 2017-04-30
WO2016039796A3 (en) 2016-06-16
EP3604335A1 (en) 2020-02-05
JP2017528476A (ja) 2017-09-28
PL3191512T3 (pl) 2020-01-31
MA40621A (fr) 2017-07-19
US20200115440A1 (en) 2020-04-16
MX2017003175A (es) 2017-06-06
SI3191512T1 (sl) 2019-09-30
SG10201902175RA (en) 2019-04-29
CN107106648A (zh) 2017-08-29
AU2015315829B2 (en) 2021-05-27
JP6560341B2 (ja) 2019-08-14
HRP20191929T1 (hr) 2020-01-10
EP3191512A2 (en) 2017-07-19
PT3191512T (pt) 2019-09-26
EP3191512B1 (en) 2019-07-24
MY179654A (en) 2020-11-11
CY1122188T1 (el) 2020-11-25
US20160075772A1 (en) 2016-03-17
MA40621B1 (fr) 2019-11-29
ES2739605T3 (es) 2020-02-03
CA2960950C (en) 2023-03-14
TWI688402B (zh) 2020-03-21
WO2016039796A2 (en) 2016-03-17
KR20170052666A (ko) 2017-05-12
AU2015315829A1 (en) 2017-04-27
CL2017000603A1 (es) 2017-10-06
TW201625302A (zh) 2016-07-16
LT3191512T (lt) 2019-09-10
DK3191512T3 (da) 2019-08-12
HUE046558T2 (hu) 2020-03-30
ME03541B (me) 2020-07-20
CL2018002962A1 (es) 2018-12-28
US20180111983A1 (en) 2018-04-26
RS59412B1 (sr) 2019-11-29
KR102564079B1 (ko) 2023-08-08
IL251063B (en) 2022-08-01
NZ730773A (en) 2022-07-01
US11407822B2 (en) 2022-08-09
CA2960950A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
CY1122188T1 (el) Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
CL2019000326A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
CY1123993T1 (el) Μεθοδος αγωγης καρκινου χρησιμοποιωντας αναστολεα σημειων ελεγχου ανοσιακου• αντισωμα που δεσμευεται σε υποδοχεα προγραμματισμενου θανατου-1 (pd-1) ή προσδετη 1 προγραμματισμενου θανατου (pd-l1)
CY1124428T1 (el) Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
BR112019006781A2 (pt) receptores de antígeno quiméricos para o tratamento de câncer
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
AR093788A1 (es) Inmunoterapia con agentes de enlace
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
BR112018008900A8 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
BR112016028726A2 (pt) métodos de tratamento de um paciente diagnosticado com diabetes tipo 1, métodos de redução, supressão, atenuação ou inibição de um ou mais sintomas associados com t1d, e métodos de tratamento de um paciente que está em risco de t1d
MX2018002467A (es) Anticuerpos y ensayos para deteccion del antigeno leucocitico (cd37).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/09/2015, OBSERVADAS AS CONDICOES LEGAIS